News

Extavia is the Novartis branded version of interferon beta-1b, a first-line disease-modifying therapy injected every other day for the treatment of multiple sclerosis (MS). Formerly known as NVF233,

Both the US and the European applications contain documentation from an extensive clinical development program that included around 6,500 people of which approximately 4,200 received liraglutide. The program

The Phase I/II study, recently reviewed and cleared by the FDA, will evaluate the safety and efficacy of the unique ovarian cancer vaccine therapy for up to 42

In addition, a higher dose administration of Iomeron 350 syringe (135 ml formulation) also received approval. Iomeron 350 and Iomeron 350 syringe are high concentration formulations of Iomeron.

The Phase II clinical trial was conducted at 28 medical centres in the US and Canada. The study was a randomized, placebo-controlled, double-blind, parallel-group evaluation of the safety,

After expenses, CuraGen will receive approximately $12 million in cash. Timothy Shannon, president and CEO of CuraGen, said: “We also retain further potential upside related to belinostat consisting

Dr Haak-Frendscho will be responsible for leading all activities at Takeda San Francisco including overall research and preclinical development, process development studies and operations for antibody therapeutics. Most

The financing consists of units priced at $1.20 per unit with each unit consisting of one share of common stock and a warrant to purchase one share of

Mr Agnello is expected to continue to serve as CFO until his successor is appointed and to remain with the company as an employee or consultant for a